
## Nandita Kachru

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3714245/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. International Journal of Geriatric Psychiatry, 2021, 36, 684-696.	2.7	8
2	Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Annals of Translational Medicine, 2021, 9, 615-615.	1.7	9
3	Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Current Medical Research and Opinion, 2021, 37, 1303-1313.	1.9	3
4	Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. Journal of Clinical Gastroenterology, 2021, 55, 891-902.	2.2	17
5	Patterns and predictors of mortality and disease progression among patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1185-1194.	3.7	37
6	Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Research in Social and Administrative Pharmacy, 2020, 16, 1670-1676.	3.0	7
7	Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosisâ€4 Score. Hepatology Communications, 2020, 4, 998-1011.	4.3	7
8	Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Journal of General Internal Medicine, 2020, 35, 2084-2093.	2.6	13
9	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine (United States), 2020, 99, e23506.	1.0	10
10	THU-388-Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data. Journal of Hepatology, 2019, 70, e325-e326.	3.7	3
11	Evaluation of Neuromuscular Blockade Reversal on Postoperative Mechanical Ventilation Time in a Cardiovascular Surgery Population. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 3348-3357.	1.3	1
12	Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data. Supportive Care in Cancer, 2018, 26, 807-812.	2.2	4
13	144: EVALUATION OF NEUROMUSCULAR BLOCKADE REVERSAL ON POSTOPERATIVE OUTCOMES IN CARDIOVASCULAR SURGERY. Critical Care Medicine, 2018, 46, 55-55.	0.9	0
14	Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Supportive Care in Cancer, 2017, 25, 1845-1851.	2.2	24
15	Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs and Aging, 2016, 33, 755-763.	2.7	11
16	Potentially inappropriate anticholinergic medication use in older adults with dementia. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 603-612.	1.5	24
17	Potentially Inappropriate Anticholinergic Medication Use in Community-Dwelling Older Adults: A National Cross-Sectional Study. Drugs and Aging, 2015, 32, 379-389.	2.7	36
18	Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data. Blood, 2015, 126, 4501-4501.	1.4	3